Agenus Inc (AGEN) is a leading biotechnology business based in the US. It opened the day at $4.05 after a previous close of $4.05. During the day the price has varied from a low of $3.98 to a high of $4.13. The latest price was $4.07 (25 minute delay). Agenus is listed on the NASDAQ and employs 328 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Agenus's share price has had significant positive movement.
Its last market close was $4.2, which is 16.19% up on its pre-crash value of $3.52 and 130.77% up on the lowest point reached during the March crash when the shares fell as low as $1.82.
If you had bought $1,000 worth of Agenus shares at the start of February 2020, those shares would have been worth $540.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,141.31.
|52-week range||$1.82 - $5.63|
|50-day moving average||$4.3686|
|200-day moving average||$3.5436|
|Wall St. target price||$8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.906|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-10-15)||-4.68%|
|1 month (2020-09-25)||1.24%|
|3 months (2020-07-24)||25.62%|
|6 months (2020-04-24)||45.88%|
|1 year (2019-10-25)||68.88%|
|2 years (2018-10-25)||127.37%|
|3 years (2017-10-25)||9.12%|
|5 years (2015-10-23)||-19.09%|
|Revenue TTM||$96.5 million|
|Gross profit TTM||$-18,291,000|
|Return on assets TTM||-35.24%|
|Return on equity TTM||0%|
|Market capitalisation||$757.6 million|
TTM: trailing 12 months
There are currently 23.1 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 0.4% up from 23.1 million last month.
There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.
Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 3.9 million). Agenus's SIR currently stands at 5.95. In other words for every 100,000 Agenus shares traded daily on the market, roughly 5950 shares are currently held short.
However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 130 shares are currently held short) or 0.1412% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 141 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.
Find out more about how you can short Agenus stock.
We're not expecting Agenus to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Agenus's shares were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.
Over the last 12 months, Agenus's shares have ranged in value from as little as $1.82 up to $5.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.9592. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
Everything we know about the Triller IPO, plus information on how to buy it.
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
Everything we know about the Wish IPO, plus information on how to buy it.
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
Everything we know about the Playboy IPO, plus information on how to buy it.
Everything we know about the iHuman IPO, plus information on how to buy it.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.